Pfizer’s Earnings: A Cosmic Conundrum for Growth Investors?

Since 2023, the stock has shed more than half its value, a decline so steep it would make a mountain feel like a molehill by comparison. This year, it has reached levels not seen since the days of dial-up modems and Blockbuster rentals. On paper, it looks like a bargain-until you remember that bargains in finance are often just the universe’s way of saying, “Here be dragons.” Investors remain wary, not just of Pfizer’s immediate future but of the entire pharmaceutical galaxy, where regulations and tariffs loom like rogue asteroids.






